A Phase I Study to Assess the Safety and Cancer‐Homing Ability of Allogeneic Bone Marrow‐Derived Mesenchymal Stem Cells in Men with Localized Prostate Cancer

Animal models show that systemically administered bone marrow‐derived mesenchymal stem cells (MSCs) home to sites of primary and metastatic prostate cancer (PC)—making them candidates to selectively deliver cytotoxic agents. To further assess this potential as a cell‐based therapeutic vehicle, a pha...

Descripción completa

Detalles Bibliográficos
Autores principales: Schweizer, Michael T., Wang, Hao, Bivalacqua, Trinity J., Partin, Alan W., Lim, Su Jin, Chapman, Carolyn, Abdallah, Rehab, Levy, Oren, Bhowmick, Neil A., Karp, Jeffrey M., De Marzo, Angelo, Isaacs, John T., Brennen, W. Nathaniel, Denmeade, Samuel R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2019
Materias:
Cell‐Based Drug Development, Screening, and Toxicology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6477003/
https://www.ncbi.nlm.nih.gov/pubmed/30735000
http://dx.doi.org/10.1002/sctm.18-0230

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6477003/
https://www.ncbi.nlm.nih.gov/pubmed/30735000
http://dx.doi.org/10.1002/sctm.18-0230

Ejemplares similares